JP2005531614A - ワクチン組成物 - Google Patents

ワクチン組成物 Download PDF

Info

Publication number
JP2005531614A
JP2005531614A JP2004512791A JP2004512791A JP2005531614A JP 2005531614 A JP2005531614 A JP 2005531614A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2005531614 A JP2005531614 A JP 2005531614A
Authority
JP
Japan
Prior art keywords
vesicle
meningococcal
strain
vesicles
bactericidal activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004512791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531614A5 (https=
Inventor
バーベラ，モラレス，ラモン，ファウスティノ
デスモン，ピエール，ミッシェル
アルヴァレス，フランシスコ，ヘサス ドミンゲス
プールマン，ジャン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
インスティチュート フィンレイ，セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, インスティチュート フィンレイ，セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2005531614A publication Critical patent/JP2005531614A/ja
Publication of JP2005531614A5 publication Critical patent/JP2005531614A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004512791A 2002-06-13 2003-06-10 ワクチン組成物 Pending JP2005531614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (2)

Publication Number Publication Date
JP2005531614A true JP2005531614A (ja) 2005-10-20
JP2005531614A5 JP2005531614A5 (https=) 2006-07-27

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004512791A Pending JP2005531614A (ja) 2002-06-13 2003-06-10 ワクチン組成物

Country Status (20)

Country Link
US (1) US20060110412A1 (https=)
EP (1) EP1565211A2 (https=)
JP (1) JP2005531614A (https=)
KR (1) KR20050049431A (https=)
CN (1) CN100387298C (https=)
AR (1) AR040204A1 (https=)
AU (1) AU2003236734A1 (https=)
BR (1) BR0311777A (https=)
CA (1) CA2488782A1 (https=)
CL (1) CL2003001192A1 (https=)
CU (1) CU23552A1 (https=)
GB (1) GB0213622D0 (https=)
MX (1) MXPA04012568A (https=)
NO (1) NO20050132L (https=)
NZ (1) NZ560766A (https=)
PE (1) PE20040562A1 (https=)
RU (1) RU2005100509A (https=)
UY (1) UY27843A1 (https=)
WO (1) WO2003105890A2 (https=)
ZA (1) ZA200409547B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
PL1973564T3 (pl) * 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011127302A2 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
AU2021364838A1 (en) * 2020-10-23 2023-06-08 Omvax, Inc. Compositions and methods for vaccination against neisseria gonorrhoeae
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6936261B2 (en) * 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物

Also Published As

Publication number Publication date
CA2488782A1 (en) 2003-12-24
WO2003105890A2 (en) 2003-12-24
AR040204A1 (es) 2005-03-16
CU23552A1 (es) 2010-07-20
RU2005100509A (ru) 2006-06-10
GB0213622D0 (en) 2002-07-24
NO20050132L (no) 2005-02-11
BR0311777A (pt) 2005-03-29
AU2003236734A1 (en) 2003-12-31
PE20040562A1 (es) 2004-10-19
UY27843A1 (es) 2003-12-31
WO2003105890A3 (en) 2004-03-25
MXPA04012568A (es) 2005-09-21
CN1668329A (zh) 2005-09-14
CN100387298C (zh) 2008-05-14
US20060110412A1 (en) 2006-05-25
CL2003001192A1 (es) 2005-01-07
ZA200409547B (en) 2006-07-26
KR20050049431A (ko) 2005-05-25
NO20050132D0 (no) 2005-01-11
EP1565211A2 (en) 2005-08-24
NZ560766A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
CN100387298C (zh) 疫苗组合物
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US20050244436A1 (en) Combination Neisserial compositions
US20170209562A1 (en) Immunogenic composition
Pinto et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups
EP1572729B1 (en) Mutant frpb protein and refolding method
EP1532168A2 (en) Method for refolding neisserial nspa protein
RU2359696C2 (ru) Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
AU2016228231A1 (en) Combination Neisserial compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101102